PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ferric Citrate→

Ferric Citrate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
3522-50-7
Molecular formula
C6H5FeO7
Molecular weight
244.94 g/mol
Drug class
Ferric iron–citrate complexphosphate-binding agent and iron source
Mechanism of action
Ferric iron binds dietary phosphate in the gastrointestinal tract, forming insoluble ferric-phosphate complexes that are eliminated in the faeces. The complex can also provide absorbable iron; these functions are product- and formulation-specific.
Indications / reported uses
  • Control of serum phosphorus in adults with chronic kidney disease on dialysis
  • Treatment of iron-deficiency anaemia in adults with chronic kidney disease not on dialysis under the applicable product indication; monitor iron indices and phosphate

Sources: US DailyMed — AURYXIA (ferric citrate) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Ferric Citrate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ferric Citrate Permitted Daily Exposure (PDE) report (the Ferric Citrate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ferric Citrate Occupational Exposure Limit (OEL) report (the Ferric Citrate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.